Regarding multiple sclerosis, one study reported that CEF(200 mg/kg/day) administered to an MOG peptide immunization mouse model of MS either from the day of immunization (permanent) or from the onset of motor manifestations (therapeutic) (Melzer et al., 2008) showed better motor outcomes than vehicle treatment. The gene discussed is MOG; the disease is myeloid sarcoma.